RE:Roche's oral selective oestrogen degrader fails in BC
Roche's April 22, 2022 announcement that it's oral selective estrogen receptor protein degrader giredestrant has come to nothing follows Pfizer's July 22, 2021 announcement that the New York company had partnered with the Phase1/2 company Arvinas to develop their estrogen receptor protein degrader ARV-471 - suggesting that the this collaboration will have a hard hill to climb.
https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-global-collaboration-develop#:~:text=NEW%20HAVEN%2C%20Conn.,Chimera)%20estrogen%20receptor%20protein%20degrader.
https://www.arvinas.com/pipeline-programs/pipeline